Skip to content. | Skip to navigation

Garvan Institute

Sections
 

About Us

 

Professor Andrew Biankin

 

Head, Pancreatic Cancer Research, Cancer Program, Garvan Institute of Medical Research; Professor, Conjoint Appointee University of New South Wales. Consultant Hepato-Pancreato-Biliary (HPB) and Upper GI Surgeon, Sydney South West Area Health Service; Chairman, NSW Pancreatic Cancer Network.

Email: a.biankin 'at' garvan.org.au
Research Group: Pancreatic Cancer

 
 
Andrew is a Surgeon Scientist who specializes in Pancreatic Diseases, particularly focusing on Pancreatic Cancer and its precursor lesions. His clinical practice is part of a specialist unit treating pancreatic disease. His research is focused on translating scientific discoveries into patient care through improved application of current therapies, early detection and novel therapeutics.
 
 
 

Education

2004    Postdoctoral Fellow, Department of Surgery, Johns Hopkins University, Baltimore
2003    PhD University of NSW
1999    F.R.A.C.S.  Royal Australasian College of Surgeons
1992    M.B., B.S. (Hons)  University of NSW
1988    B. Med. Sc. University of NSW

Awards and Honours

2010 Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research
2008 Hirshberg Award for Pancreatic Cancer, American Pancreatic Association
2008 Cancer Institute NSW Career Development and Support Fellowship
2007 Cancer Institute NSW Premier's Award for Outstanding  Cancer Research Fellow
2005 Cancer Institute NSW Career Development and Support Fellowship
2005 Cure Cancer Australia Young Investigator of the Year
2005 Travel Award, Surgical Research Society of Australia
2004 Excellence in Translational Research Award, Johns Hopkins University
2003 Thesis Prize, Garvan Institute of Medical Research
2003 - 2006 Neil Hamilton Fairley Postdoctoral Fellowship, National Health & Medical Research Council
2003 Travelling Fellowship, Royal Australasian College of Surgeons
2002 Travelling Fellowship, St Vincent's Clinic Foundation
2002 Warren Fellowship (International Hepato-Pancreato-Biliary Association)
2001 Annual St Vincent's Campus Research Symposium Award for excellence in research
2001 Young Investigator Award, Johns-Hopkins Medical Institutions, Baltimore, Maryland, USA/The Lustgarten Foundation for Pancreatic Cancer Research
2001 Travelling Fellowship, International Surgical Society
2000 Annual St Vincent's Campus Research Symposium Award for excellence in poster presentation.
1999 - 2002 National Health & Medical Research Council, Medical Postgraduate Scholarship
1999 - 2002 Sir Roy McCaughey Fellowship, Royal Australasian College of Surgeons
1999 Di Boyd Cancer Research Award, St Vincent's Clinic Foundation


Publications

Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res.15;70(22):9391-401. Epub Sep 21.

Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, Liu T. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene. 29(44):5957-68. Epub Aug 9.

Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, O'Connell PJ, Loudovaris T, Kay TW, Kulkarni RN, Okada T, Wang XL, Yim SH, Shah Y, Grey ST, Biankin AV, Kench JG, Laybutt DR, Gonzalez FJ, Kahn CR, Gunton JE. (2010) Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest. 120(6):2171-83. doi: 10.1172/JCI35846. Epub May 5

International Cancer Genome Consortium; Member of writing team (2010). International network of Cancer Genome Projects. Nature 464:993-8

Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, Chang DK, Skalicky DA, Morey AL, Lee CS, O’Toole SA, Pinese M, Kuo SCL, Susanto JM, Cosman PH, Lindeman GJ, Visvader JE, Merrett ND, Musgrove EA, Henshall SM, Sutherland RL. (2009) Expression of S100A2 calcium-binding protein Predicts Response to Pancreatectomy for Pancreatic Cancer. Gastroenterolgy. 137:558-68

Pinese M, Scarlett CJ, Kench JG, Colvin EK, Segara D, Henshall SM, Sutherland RL, Biankin AV. (2009) Messina: a novel analysis tool to identify biologically relevant molecules in disease. PLoS One. 4(4):e5337. Epub Apr 28.

Chang DK, Johns AL, Merrett ND et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27(17):2855-2862.

Leong RWL, Nguyen N, Meredith CG et al. In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology 2008; 135(6):1870-1876.

Pasca di Magliano M, Biankin AV, Heiser PW et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007; 2(11):e1155.

Henshall SM, Horvath LG, Quinn DI et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98(19):1420-1424.

 

Search for all publications by Andrew Biankin

 
 
 

Areas of Interest

pancreatic cancer, translational research
 

News

 

CINSW presents Premier’s Awards to two Garvan Researchers

MEDIA RELEASE: 15 Jul 2011
At a gala dinner held last night, the Cancer Institute NSW presented Dr Alex Swarbrick with the CINSW 2011 Premier’s Fellow of the Year Award and Dr David Chang with the CINSW 2011 Premier’s Scholar of the Year Award, as well as a Pfizer Oncology International Studentship.
 
 

Helping pancreatic cancer surgeons make tiebreaker decisions

MEDIA RELEASE: 15 Apr 2011
Garvan researchers have identified two ‘biomarkers’ that appear to have the ability to predict patient survival after surgery for pancreatic cancer before the operation takes place. It is the first predictive tool of its kind for this most deadly of cancers. The American Society of Clinical Oncology (ASCO) highlights the finding in its current newsletter (ASCO Post) – distributed globally to a broad audience of cancer professionals.
 
 

Personalised medicine for cancer patients in a new technology era

MEDIA RELEASE: 15 Apr 2010
Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium (ICGC) describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.
 
 

Personal tools